Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma

Completed

• Conditions: Carbonic Anhydrase IX; Triple Negative Breast Cancer

• Registration Number: NCT06309459
• Lead Sponsor: Kahramanmaras Sutcu Imam University

Brief Summary

Triple-negative breast carcinoma is characterized by the absence of estrogen receptors, progesterone receptors, and HER2/neu receptors. Carbonic anhydrase IX (CA IX) is a tumor-associated cell surface glycoprotein that is involved in adaptation to hypoxia-induced acidosis and plays a role in cancer progression. This study aimed to investigate CA IX expression in TNBC and its relationship with treatment effect.

Detailed Description

Tru-cut biopsy materials, sent to our hospital pathology laboratory between August 2018 and May 2023, will be examined. Invasive carcinoma cases will be evaluated according to estrogen, progesterone, and HER 2 receptor levels. Triple-negative tumor cases were isolated and those cases who underwent breast resection in our hospital after receiving neoadjuvant chemotherapy (Adriamycin, cyclophosphamide, and then paclitaxel for 4 cycles) were included in the study.

Study Timeline

• Study Start: 2018-08-01
• Primary Completion: 2023-05-01
• Study Completion: 2023-05-01
• Study First Submitted: 2024-01-10
• Status Verified: 2024-03
• Study First Submitted QC: 2024-03-06
• Last Update Submitted: 2024-03-06
• Study First Posted: 2024-03-13
• Last Update Posted: 2024-03-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Older than 18 years
• Triple-negative mastectomy cases
• Patients whose data can be available
• Patients who were operated in our hospital

Exclusion Criteria

• Younger than 18 years
• Not triple negative mastectomy cases
• Patients with missing data
• Patients who were operated in another hospital

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Poor prognostic factors in patients with TNBC	2018-2023	Higher staining CA IX levels (≥ 10%) in TNBC patients' pathological specimens is a poor prognostic factor
The treatment success with inhibiting the CA IX enzyme levels' effectiveness	2018-2023	Treatment success in TNBC patients by evaluating changes in CA IX staining levels

Trial Locations

Locations (1)

Kahramanmaraş Sütçü İmam University; 🇹🇷 Kahramanmaraş, Turkey